Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) were down 7.6% during mid-day trading on Tuesday. The company traded as low as $19.88 and last traded at $19.7840. 1,246,354 shares traded hands during trading, a decline of 71% from the average session volume of 4,276,905 shares. The stock had previously closed at $21.41.
Wall Street Analysts Forecast Growth
REPL has been the subject of several analyst reports. Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a report on Friday, August 7th. Wolfe Research raised Replimune Group to an "outperform" rating in a research report on Tuesday, August 4th. Cantor Fitzgerald restated an "overweight" rating on shares of Replimune Group in a research note on Monday, October 5th. Piper Sandler upped their target price on Replimune Group from $14.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday. Finally, Wall Street Zen upgraded Replimune Group from a "sell" rating to a "hold" rating in a research note on Saturday, October 31st. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.17.
Read Our Latest Stock Report on Replimune Group
Replimune Group Stock Down 8.0%
The business's 50 day moving average is $14.89 and its 200 day moving average is $10.11. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -7.06 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11.
Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.24. Sell-side analysts anticipate that Replimune Group, Inc. will post -2.40 earnings per share for the current year.
Insider Activity at Replimune Group
In related news, Director Joseph P. Slattery sold 5,200 shares of Replimune Group stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $21.80, for a total value of $113,360.00. Following the sale, the director directly owned 1,467 shares in the company, valued at approximately $31,980.60. The trade was a 78.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Kapil Dhingra sold 21,500 shares of Replimune Group stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $19.00, for a total value of $408,500.00. Following the completion of the sale, the director directly owned 21,669 shares in the company, valued at $411,711. This represents a 49.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.40% of the stock is currently owned by company insiders.
Institutional Trading of Replimune Group
Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Replimune Group during the 2nd quarter worth about $99,171,000. Montanova Capital LLC lifted its position in Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company's stock valued at $48,595,000 after buying an additional 168,000 shares during the last quarter. Marshall Wace LLP acquired a new position in Replimune Group in the third quarter valued at about $50,516,000. Opaleye Management Inc. purchased a new position in Replimune Group during the second quarter worth about $15,332,000. Finally, Dimensional Fund Advisors LP boosted its stake in Replimune Group by 1.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company's stock worth $8,719,000 after buying an additional 20,742 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.
Replimune Group Company Profile
(
Get Free Report)
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company's investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.